Should I buy or sell Achieve Life Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACHV shares. View ACHV analyst ratings or view top-rated stocks .

What is Achieve Life Sciences' stock price target for 2024?

2 analysts have issued 12-month price objectives for Achieve Life Sciences' stock. Their ACHV share price targets range from $17.00 to $20.00. On average, they predict the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 222.4% from the stock's current price. View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts .

How have ACHV shares performed in 2023?

Achieve Life Sciences' stock was trading at $2.45 at the beginning of 2023. Since then, ACHV shares have increased by 136.3% and is now trading at $5.79. View the best growth stocks for 2023 here .

When is Achieve Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our ACHV earnings forecast .

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.07. During the same period in the previous year, the business earned ($0.76) EPS.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences's stock reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Gran Tierra Energy (GTE) , Bionano Genomics (BNGO) , Novan (NOVN) , Aeterna Zentaris (AEZS) , Zosano Pharma (ZSAN) , CNBX Pharmaceuticals (CNBX) , KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI) .

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include LPL Financial LLC (0.78%), Raymond James & Associates (0.69%), Northern Trust Corp (0.37%), Manchester Financial Inc. (0.09%), Group One Trading L.P. (0.00%) and Belvedere Trading LLC (0.00%). View institutional ownership trends .

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Achieve Life Sciences Stock Price, News & Analysis (NASDAQ:ACHV)

$5.79

+0.07 (+1.22%)

(As of 11/30/2023 ET)

Compare

Today's Range: $5.70
▼
$5.87
50-Day Range: $3.65
▼
$5.86
52-Week Range: $2.36
▼
$10.30

Volume: 9,395 shs
Average Volume: 101,069 shs
Market Capitalization: $122.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.67

Achieve Life Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 222.4% Upside
$18.67 Price Target
Short Interest: Bearish
3.24% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.27
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.57) to ($1.41) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

719th out of 949 stocks

Diagnostic Substances Industry

9th out of 13 stocks

3.5

Analyst's Opinion

Consensus Rating
Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.67, Achieve Life Sciences has a forecasted upside of 222.4% from its current price of $5.79.
Amount of Analyst Coverage
Achieve Life Sciences has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.24% of the outstanding shares of Achieve Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Achieve Life Sciences has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Achieve Life Sciences has recently decreased by 1.39%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Achieve Life Sciences does not currently pay a dividend.
Dividend Growth
Achieve Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACHV.

2.4

News and Social Media Coverage

News Sentiment
Achieve Life Sciences has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Achieve Life Sciences this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Achieve Life Sciences is held by insiders.
Percentage Held by Institutions
43.65% of the stock of Achieve Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.57) to ($1.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Achieve Life Sciences is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Achieve Life Sciences is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Achieve Life Sciences has a P/B Ratio of 30.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Achieve Life Sciences Stock (NASDAQ:ACHV)

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

ACHV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACHV Stock News Headlines

November 29, 2023 | americanbankingnews.com

Achieve Life Sciences (NASDAQ:ACHV) Share Price Passes Above 200-Day Moving Average of $5.15

November 12, 2023 | markets.businessinsider.com

Potential Growth and Success: Jason McCarthy’s Buy Recommendation for Achieve Life Sciences Amid Promising Cytisinicline Progress

November 30, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 11, 2023 | finance.yahoo.com

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2023 Earnings Call Transcript

November 10, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (XRAY), GoodRx Holdings (GDRX) and Achieve Life Sciences (ACHV)

November 10, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vor Biopharma (VOR), Gilead Sciences (GILD) and Achieve Life Sciences (ACHV)

November 10, 2023 | finance.yahoo.com

ACHV: Ancillary Studies Complete

November 10, 2023 | finance.yahoo.com

Q3 2023 Achieve Life Sciences Inc Earnings Call

November 30, 2023 | Tomorrow Investor (Ad)

Why Microsoft Just Placed A Huge Bet On Nuclear

Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.

November 9, 2023 | finance.yahoo.com

Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update

November 2, 2023 | msn.com

Achieve Credit Union surprises teacher at Horizon Science Academy of Lorain with gift card

November 2, 2023 | markets.businessinsider.com

Achieve announces close of $157.5 million, AAA-rated personal loan securitization

October 30, 2023 | markets.businessinsider.com

Achieve invests in top talent with appointment of Chief Operating Officer and Chief Security Officer

October 26, 2023 | finance.yahoo.com

Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023

October 23, 2023 | msn.com

College Achieve Public Schools Named Semifinalist for $1M Education Innovation Prize

October 19, 2023 | msn.com

Together We Achieve gears up for winter with community coat drive

September 28, 2023 | nj.com

College Achieve Central beats Roselle Park to extend win streak - Boys soccer recap

September 27, 2023 | nj.com

College Achieve Central beats Rutgers Prep to extend win streak - Boys soccer recap

September 26, 2023 | msn.com

College Achieve Public Schools Named Finalist for 2023 Yass Prize, Aiming to Transform Education

September 22, 2023 | nj.com

Girls soccer recap: Gabriela Garcia scores twice as College Achieve tops Lincoln Leadership

September 22, 2023 | nj.com

College Achieve Central defeats Delaware Valley - Boys soccer recap

September 20, 2023 | villagegreennj.com

The Achieve Foundation Newstead 5K is Saturday, September 30

September 19, 2023 | usnews.com

Xi Says China, US 'Should and Must' Achieve Peaceful Co-Existence

September 15, 2023 | nj.com

Summit shuts out College Achieve Central - Boys soccer recap

September 1, 2023 | msn.com

Exit Realty Achieve: Making Realty A Supportive, Collaborative Business

August 16, 2023 | finance.yahoo.com

ACHV: 2Q:23 Results

August 16, 2023 | finance.yahoo.com

Q2 2023 Achieve Life Sciences Inc Earnings Call

See More Headlines

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/16/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ACHV
CUSIP: 68230A10
CIK: 949858
Web: achievelifesciences.com
Phone: (604) 210-2217
Fax: 425-686-1600
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.67
High Stock Price Target: $20.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +222.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -632.85%
Return on Assets: -136.78%

Debt

Debt-to-Equity Ratio: 4.02
Current Ratio: 5.36
Quick Ratio: 5.36

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: 30.47

Miscellaneous

Outstanding Shares: 21,170,000
Free Float: 20,743,000
Market Cap: $122.57 million
Optionable: Not Optionable
Beta: 1.44

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Richard A. B. Stewart (Age 64)
Executive Chairman
Comp: $575k
Mr. John A. Bencich M.B.A. (Age 46)
CEO & Director
Comp: $733.12k
Dr. Cindy Jacobs M.D. (Age 65)
Ph.D., President, Chief Medical Officer & Director
Comp: $614.25k
Mr. Jerry Wan (Age 41)
Principal Accounting Officer
Dr. Anthony Clarke (Age 67)
Chief Scientific Officer
Comp: $546k
Ms. Jaime Xinos
Executive Vice President of Commercial

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACHV Stock Analysis - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings or view top-rated stocks.
What is Achieve Life Sciences' stock price target for 2024?: 2 analysts have issued 12-month price objectives for Achieve Life Sciences' stock. Their ACHV share price targets range from $17.00 to $20.00. On average, they predict the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 222.4% from the stock's current price.
View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts.
How have ACHV shares performed in 2023?: Achieve Life Sciences' stock was trading at $2.45 at the beginning of 2023. Since then, ACHV shares have increased by 136.3% and is now trading at $5.79.
View the best growth stocks for 2023 here.
When is Achieve Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ACHV earnings forecast.
How were Achieve Life Sciences' earnings last quarter?: Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.07. During the same period in the previous year, the business earned ($0.76) EPS.

When did Achieve Life Sciences' stock split?: Achieve Life Sciences's stock reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Achieve Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).
Who are Achieve Life Sciences' major shareholders?: Achieve Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include LPL Financial LLC (0.78%), Raymond James & Associates (0.69%), Northern Trust Corp (0.37%), Manchester Financial Inc. (0.09%), Group One Trading L.P. (0.00%) and Belvedere Trading LLC (0.00%).
View institutional ownership trends.
How do I buy shares of Achieve Life Sciences?: Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACHV) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial